Literature DB >> 7518565

Protein-tyrosine phosphatase activity of CD45 is activated by sequential phosphorylation by two kinases.

D R Stover1, K A Walsh.   

Abstract

We describe a potential regulatory mechanism for the transmembrane protein-tyrosine phosphatase CD45. Phosphorylation on both tyrosine and serine residues in vitro results in an activation of CD45 specifically toward one artificial substrate but not another. The activation of these kinases appears to be order dependent, as it is enhanced when phosphorylation of tyrosine precedes that of serine but phosphorylation in the reverse order yields no activation. Any of four protein-tyrosine kinases tested, in combination with the protein-serine/threonine kinase, casein kinase II, was capable of mediating this activation in vitro. The time course of phosphorylation of CD45 in response to T-cell activation is consistent with the possibility that this regulatory mechanism is utilized in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518565      PMCID: PMC359072          DOI: 10.1128/mcb.14.8.5523-5532.1994

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  49 in total

1.  Mutational analysis of CD45. A leukocyte-specific protein tyrosine phosphatase.

Authors:  P Johnson; H L Ostergaard; C Wasden; I S Trowbridge
Journal:  J Biol Chem       Date:  1992-04-25       Impact factor: 5.157

Review 2.  The leukocyte common antigen family.

Authors:  M L Thomas
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

3.  The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and alpha 2-6 sialyltransferase, CD75, on B cells.

Authors:  I Stamenkovic; D Sgroi; A Aruffo; M S Sy; T Anderson
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

4.  A functional complex is formed in human T lymphocytes between the protein tyrosine phosphatase CD45, the protein tyrosine kinase p56lck and pp32, a possible common substrate.

Authors:  B Schraven; H Kirchgessner; B Gaber; Y Samstag; S Meuer
Journal:  Eur J Immunol       Date:  1991-10       Impact factor: 5.532

Review 5.  CD45. A prototype for transmembrane protein tyrosine phosphatases.

Authors:  I S Trowbridge
Journal:  J Biol Chem       Date:  1991-12-15       Impact factor: 5.157

Review 6.  Specialized protein tyrosine kinase proto-oncogenes in hematopoietic cells.

Authors:  R M Perlmutter; J D Marth; S F Ziegler; A M Garvin; S Pawar; M P Cooke; K M Abraham
Journal:  Biochim Biophys Acta       Date:  1989-02

7.  Demonstration that the leukocyte common antigen CD45 is a protein tyrosine phosphatase.

Authors:  N K Tonks; H Charbonneau; C D Diltz; E H Fischer; K A Walsh
Journal:  Biochemistry       Date:  1988-11-29       Impact factor: 3.162

8.  Acid and base hydrolysis of phosphoproteins bound to immobilon facilitates analysis of phosphoamino acids in gel-fractionated proteins.

Authors:  M P Kamps; B M Sefton
Journal:  Anal Biochem       Date:  1989-01       Impact factor: 3.365

9.  Isoform-specific associations of CD45 with accessory molecules in human T lymphocytes.

Authors:  U Dianzani; V Redoglia; F Malavasi; M Bragardo; A Pileri; C A Janeway; K Bottomly
Journal:  Eur J Immunol       Date:  1992-02       Impact factor: 5.532

10.  Changes in CD45 isoform expression accompany antigen-induced murine T-cell activation.

Authors:  M L Birkeland; P Johnson; I S Trowbridge; E Puré
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

View more
  2 in total

Review 1.  Receptor protein tyrosine phosphatase from stem cells to mature glial cells of the central nervous system.

Authors:  Smaragda Lamprianou; Sheila Harroch
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

2.  Receptor protein tyrosine phosphatase alpha participates in the m1 muscarinic acetylcholine receptor-dependent regulation of Kv1.2 channel activity.

Authors:  W Tsai; A D Morielli; T G Cachero; E G Peralta
Journal:  EMBO J       Date:  1999-01-04       Impact factor: 11.598

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.